Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3Lymphoid 3Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Recurrence 1Ovarian Neoplasms 1

Interventions

Paclitaxel 581Carboplatin 527Cisplatin 355Bevacizumab 256pembrolizumab 226Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 126Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 90niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 73Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 56Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ispinesib × Gynecologic × Clear all
NCT00097409 2010-10-04

Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer

GlaxoSmithKline

Phase 2 Completed
35 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡